109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血红蛋白作为慢性阻塞性肺疾病（COPD）的可治疗特征：基于 NHANES 数据的血红蛋白水平与全因死亡率的回顾性观察队列研究
Received 1 May 2025
Accepted for publication 11 October 2025
Published 25 October 2025 Volume 2025:20 Pages 3473—3481
DOI https://doi.org/10.2147/COPD.S537888
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Richard Russell
Dongxiang Ji,1 Hewei Yu2
1Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China; 2Department of Otorhinolaryngology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China
Correspondence: Hewei Yu, Email 782610491@qq.com
Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. Hemoglobin (HGB) abnormalities, including anemia and secondary polycythemia, are common comorbidities in COPD patients, yet their association with mortality remains less clear. This study aimed to investigate the relationship between HGB levels and all-cause mortality in COPD patients and to evaluate whether HGB could serve as a treatable trait in COPD.
Methods: We conducted a retrospective observational cohort study using data from the National Health and Nutrition Examination Survey (NHANES, 2013– 2018). A total of 544 COPD patients were included. Multivariable Cox regression was conducted to assess HGB-mortality associations, adjusting for age, sex, BMI, smoking status, and comorbidities. Nonlinear relationships were examined using generalized additive models with threshold effect analysis. Stratified analyses were performed by sex, age, and comorbidity status.
Results: Among 544 COPD patients, HGB levels demonstrated a significant nonlinear association with all-cause mortality, with a critical inflection point identified at 14.2 g/dL. Below this threshold, each 1g/dL in HGB was associated with reduced mortality (adjusted HR=0.73, 95% CI: 0.61– 0.79, P< 0.0001). Above 14.2g/dL, however, no significant association was observed (HR=1.24, 95% CI: 0.98– 1.55, P=0.0775). Although stratified analyses suggested variation in HR across subgroups (including males, elderly > 65 years, smokers, and those with cardiovascular disease), interaction tests did not reach statistical significance (all P-interaction > 0.05), indicating no evidence of effect modification. Smoothing curves supported this nonlinear relationship, showing decreasing mortality risk with rising HGB until the threshold, beyond which risk stabilized with a slight non-significant upward trend.
Conclusion: This study identifies a nonlinear relationship between HGB levels and mortality in COPD, establishing 14.2 g/dL as a critical threshold that supports anemia’s inclusion in the COPD “treatable traits” framework. Below this value, increasing HGB is associated with reduced mortality, whereas above it no further benefit is observed. Clinicians should prioritize HGB monitoring in high-risk subgroups (elderly males, smokers, and cardiac comorbidities).
Keywords: COPD, all-cause mortality, anemia, treatable traits
1Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China; 2Department of Otorhinolaryngology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, People’s Republic of China
Correspondence: Hewei Yu, Email 782610491@qq.com
Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. Hemoglobin (HGB) abnormalities, including anemia and secondary polycythemia, are common comorbidities in COPD patients, yet their association with mortality remains less clear. This study aimed to investigate the relationship between HGB levels and all-cause mortality in COPD patients and to evaluate whether HGB could serve as a treatable trait in COPD.
Methods: We conducted a retrospective observational cohort study using data from the National Health and Nutrition Examination Survey (NHANES, 2013– 2018). A total of 544 COPD patients were included. Multivariable Cox regression was conducted to assess HGB-mortality associations, adjusting for age, sex, BMI, smoking status, and comorbidities. Nonlinear relationships were examined using generalized additive models with threshold effect analysis. Stratified analyses were performed by sex, age, and comorbidity status.
Results: Among 544 COPD patients, HGB levels demonstrated a significant nonlinear association with all-cause mortality, with a critical inflection point identified at 14.2 g/dL. Below this threshold, each 1g/dL in HGB was associated with reduced mortality (adjusted HR=0.73, 95% CI: 0.61– 0.79, P< 0.0001). Above 14.2g/dL, however, no significant association was observed (HR=1.24, 95% CI: 0.98– 1.55, P=0.0775). Although stratified analyses suggested variation in HR across subgroups (including males, elderly > 65 years, smokers, and those with cardiovascular disease), interaction tests did not reach statistical significance (all P-interaction > 0.05), indicating no evidence of effect modification. Smoothing curves supported this nonlinear relationship, showing decreasing mortality risk with rising HGB until the threshold, beyond which risk stabilized with a slight non-significant upward trend.
Conclusion: This study identifies a nonlinear relationship between HGB levels and mortality in COPD, establishing 14.2 g/dL as a critical threshold that supports anemia’s inclusion in the COPD “treatable traits” framework. Below this value, increasing HGB is associated with reduced mortality, whereas above it no further benefit is observed. Clinicians should prioritize HGB monitoring in high-risk subgroups (elderly males, smokers, and cardiac comorbidities).
Keywords: COPD, all-cause mortality, anemia, treatable traits